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A B S T R A C T
Purpose: In the UK, there are over 40,000 childhood cancer survivors (CCS); this figure grows approximately
1300 annually. Two-thirds are at risk of developing serious disabling or life-threatening conditions due to ad-
verse late effects of the cancer or treatment received in childhood. Life-long, follow-up care for the surveillance
and management of late effects is recommended. This study explored CCS’ views and experiences of long-term
follow-up (LTFU) care within a cancer centre.
Methods: Paper questionnaires (n = 113) and qualitative interviews (n = 13).
Results: The majority (n = 83, 80%) of CCS reported being satisfied with their LTFU care and felt that it was
important to attend long-term survivorship follow-up (n = 97, 86%). However, some were not well informed
about their cancer treatment history, purpose for attending the clinic or the potential for late effects. Barriers
associated with LTFU included; provision of information, lack of interpersonal relationships, practical and lo-
gistic challenges.
Conclusions: Barriers identified can be addressed through strategies including provision of verbal and written
information and care plans to increase CCS’ knowledge of their cancer history, risk of late effects and the purpose
of LTFU care, both at transition and throughout their survivorship journey; patient-centred services that enhance
patient choice and flexibility of access to multiple specialities; and use of risk stratified pathways to encourage
supported self-management based on cancer type, co-morbidity, and level of professional involvement required.
Improving regular provision of information at critical time-points, and exploring a flexible, patient-centred
delivery of LFTU care based on risk, could increase attendance and self-management in CCS.
1. Introduction
It is estimated that approximately 300,000 cases of childhood
cancer are diagnosed annually worldwide in children and young people
under the age of 19, with an estimated 80,000 cancer-related deaths
(IARC, 2016 Steliarova-Foucher et al., 2017). The UK has one of the
lowest rates of childhood cancer in Europe, with around 1821 new
cases in 0–14 year olds (Children's Cancer and Leukaemia Group, 2014)
2630 adolescent and young adults (aged 15–24 years) diagnosed each
year; incidence rates have increased over the last decade (Cancer
Research UK., 2009). Across Europe approximately 80–84% of child-
hood cancer patients now reach five-year survival, and around 70% will
survive 10 years following end of treatment (Taylor et al., 2004; Gatta
et al., 2008; Cancer Research UK., 2009; Ward et al., 2014). However,
long-term childhood cancer survivors (CCS) are at risk of premature
mortality or substantial morbidity due to adverse late effects of either
the cancer diagnosis or subsequent treatment received (Lackner et al.,
2000, Signorelli et al., 2017). The accumulative incidence of late effects
also increases with age, with elevated risk for survivorship beyond 35
years often resulting in serious disabling or life-threatening events by
50 years of age (Armstrong et al., 2014). Recent figures suggest that by
age 45, 95% of CCS will have a chronic health condition or experience a
disabling life-threatening chronic condition (Howard et al., 2018).
Late effects vary depending on the type of cancer and treatment
received but can include secondary malignancies, endocrine and me-
tabolic disorders, pulmonary dysfunction, cardiovascular disease,
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infertility, cognitive impairment and disorders of growth development
[Bhatia and Landier (2005); Michel et al. (2009); Howard et al. (2018).
Cancer survivorship is therefore viewed as a distinctive phase of cancer
care, and it is essential that appropriate, long-term follow-up (LTFU) of
this patient population is conducted to prevent, detect and treat adverse
late effects (Edgar et al., 2013; Howard et al., 2018).
Despite evidence, which suggests that LTFU care is beneficial to the
long-term outcomes of CCS, there is no conclusive evidence of an op-
timal healthcare model (Howard et al., 2018). Different models of
follow-up care exist for CCS including primary care provided by a fa-
mily doctor or general practitioner (GP), specialist centre led care, and
shared care services. Whatever the health care model for LTFU care, a
key time to engage with CCS is at the point of transition to adult ser-
vices (Freyer, 2010; Henderson et al., 2010; Signorelli et al., 2017).
Unfortunately, rates of non-attendance at LTFU clinics can vary from
15% (Klosky et al., 2008) to 82% (Iyer et al., 2013). Poor attendance at
LTFU clinics has been linked to positive self-perception of current
health in adulthood (Cox et al., 2012), experiencing fewer late effects
(Klosky et al., 2008; Iyer et al., 2013), wishing to ‘draw a line’ under
their cancer and return to a normal life (Earle et al., 2005), fear of
potential late effects from cancer treatment (Michel et al., 2011) and
the challenge of attending multiple specialities or appointments (Eiser,
2007). CCS have also expressed barriers and challenges associated with
attending clinic appointments, particularly when key information and
test results are not available and this may influence a patient's decisions
not to attend subsequent appointments (Earle et al., 2005). It has also
been suggested that non-attendance may be due to CCS having high
levels of self-efficacy in deciding whether to attend (Michel et al.,
2011). The aim of this study was to explore adult CCS′ reported views
and experiences of long-term follow-up survivorship care.
2. Methods
A mixed-method, sequential, explanatory design (Cresswell, 2005)
using questionnaires and qualitative interviews examined the views and
experiences of CCS of attending long-term follow-up care.
2.1. Setting and study participants
This study took place with CCS who transferred from a regional
children's hospital between the ages of 16 and 20 to one specialised bi-
monthly LTFU survivorship clinic situated within an adult-focused
cancer treatment centre in the UK. The point of transition to the LTFU
clinic is a patient-centred process which is primarily age dependent
rather than the time since treatment ended. For example, a well patient
who was treated for acute lymphoblastic leukaemia at three years of
age would transition at the younger end of the age range, whereas a
patient treated for a brain tumour aged 15 would typically transition
nearer to age 20 years. The clinic is run by both a paediatric and adult
oncologist. CCS are initially offered an annual follow-up; the frequency
of subsequent follow-up appointments are risk-stratified to meet in-
dividual patient need. An alternative telephone based follow up service
is offered to patients with fewer needs or those who have a history of
non-attendance at face-to-face clinics, although patients can opt back in
to the face-to-face clinics at any time.
We recruited CCS aged 18 years and over, who had completed ac-
tive cancer treatment, and were registered as patients of the long-term
survivorship clinic. A study information pack, which included a patient
information sheet and paper-based questionnaire, were posted to the
home address of all CCS by the clinical team. To gain responses from
those CCS that routinely did not attend appointments an additional
flyer was sent out mid-data collection to a targeted population of CCS
who had not attended clinic inviting them again to participate. CCS
were prompted to contact the study team if they had any questions
about participation. Participants were invited to send their contact
details to the study team on a slip if they agreed to participate in a semi-
structured interview and were contacted to arrange a convenient time.
2.2. Data collection
The first phase of the study collected structured data using a short,
anonymous, self-completed paper-based questionnaire (Nov 2015 and
Jan 2016). The questionnaire was developed by the study team, in-
formed by the current literature, clinical expertise and through con-
sultation with eight patients. The questionnaire was divided into three
sections which consisted of 19 closed categorical and Likert scale
questions and four open-ended response questions. The questionnaire
gathered demographic, diagnosis and treatment information, patients’
views and opinions of attending long-term follow-up care and knowl-
edge about their cancer treatment and ongoing provision of care.
Patients returned the anonymous questionnaire through the post to the
study team. A copy of the questionnaire is available from the corre-
sponding author upon request.
Semi-structured interviews gathered more in-depth information on
CCS′ views and experiences of attending the long-term survivor clinic
and knowledge regarding diagnosis, treatment and long-term follow-
up. The interview guide questions can be seen in Table 1. Interviews
were conducted between Nov 2015 and Jan 2016 by experienced
qualitative researchers either via face-to-face, which were conducted at
the survivors' homes or via telephone, depending on the patient's pre-
ference. Interviews were audio-recorded with the participant's permis-
sion and transcribed.
2.3. Analysis
Data from the paper-based questionnaires were entered into IBM
SPSS Statistics for Windows (Version 22.0. Armonk, NY: IBM Corp.)
Descriptive statistics were used to summarise the closed/categorical
and Likert Scale responses structured data (e.g. frequencies and per-
centages). Analysis of the semi-structured interview data was inductive
and adhered to the six key phases outlined in Braun & Clarke's thematic
analysis process; familiarisation of data; coding the data; searching for
themes; reviewing themes; defining and naming themes and producing
the report (Braun and Clarke, 2006). The study team conducted initial
analysis on six transcripts and the codes were used as a framework for
Table 1
Interview guide.
1. What is your current age?
2. What type of cancer were you treated for as a child?
3. What type of treatment did you have?
4. How long ago did you finish treatment for your childhood cancer?
5. Do you attend a Late Effects Clinics (LEC) at the hospital or use the telephone
consultation service?
6. Do you currently have a treatment/survivorship care plan outlining your follow up
care needs?
YOUR VIEWS
7. Do you feel well informed about the purpose of follow up care at the Late Effects
Clinic?
8. How important is it to you that you attend regular follow up care at the Late Effects
Clinic?
YOUR EXPERIENCE OF APPOINTMENTS AND ATTENDANCE
9. Can you tell me about your experience of attending appointments with the Late
Effects Clinics/phone service?
10. Have you experienced any health issues related to your childhood cancer?
11. Is there anything that makes it difficult for you to attend the Late Effects Clinics/
phone service?
12. How satisfied are you with your Late Effects Clinics/phone service appointments
when you do attend?
13. What do you think could be done to improve the current Late Effects Clinics/
phone service?
14. Is there anything else you would like to say about the Late Effects Service or
follow up care?
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developing a coding scheme for the other transcripts. These codes were
then grouped into themes and discussed between the study team to
define, shape and develop themes.
2.4. Ethics approval
The study obtained ethical committee approval through the authors
employing institution [SC21] and approved as service evaluation (using
the Health Research Authority decision tool (HRA, 2018) by the par-
ticipating hospital Trust. Informed consent was obtained from all par-
ticipants who were involved in the qualitative interviews, consent was
implied by those participants returning the questionnaire.
3. Results
The questionnaire was distributed to 458 CCS of which 113 parti-
cipants returned the questionnaire (25% response rate). The mean age
of respondents was 30 years of age (range of 19–70 years). Thirteen CCS
(n = 7 male, n = 6 female) participated in the semi-structured inter-
views by phone (n = 9) or face-to-face (n = 4). The mean age of
participants who took part in the semi-structured interviews was 36
years of age (range of 21–71 years). The mean interview duration was
30 min, with individual interviews ranging from 11 to 55 min.
Respondents received treatment for a range of childhood cancers which
are presented in Table 2. Most received a range of treatments consisting
of chemotherapy, radiotherapy, surgery, and bone marrow transplants
or a combination of each of these treatments. The majority of partici-
pants that responded to the paper-based questionnaire reported acces-
sing the LTFU service through physical attendance at the clinic (n = 92,
84%). Only seven (6%) respondents used telephone services alone and
11 (10%) respondents reported attending the clinic as well as using
telephone services.
The key findings from the questionnaires and interviews are pre-
sented together under three themed headings: (i) motivation for at-
tending long-term follow-up care and (ii) knowledge of cancer treat-
ment and potential late effects. (iii) suggested improvements to the
current service. All quotes or open comment are represented as a
questionnaire respondent (QR) or interview respondent (IR).
3.1. Motivation for attending long-term follow-up
The majority (n = 83, 80%) of CCS reported being satisfied with
their LTFU care and felt that it was very important to attend long-term
survivorship follow-up (n = 97, 86%). The interviews explored reasons
as to the importance associated with long-term follow-up as well as
factors that motivated CCS to attend clinic. CCS discussed that atten-
dance at follow-up enabled them to access health information about
late effects that they had either experienced or may have been experi-
encing at the time.
‘I only see him every 3 years sort of thing. If anything's built up over that
time I can go what's this, what's that, what's that … its little things with
me, it's more moles, its family planning sort of things. It's little things like
that that I need information on’ (IR 1)
Specialist information provided by the clinical team were valuable
to CCS who reported receiving inadequate expertise, resources and
information outside of their specialist services.
‘It's your opportunity to talk to somebody that understands about your
particular situation, I find that a lot of doctors, simply don't really un-
derstand.’ (IR 7)
Some CCS discussed reasons for attending the clinic which included
feeling indebted to their doctors for their childhood cancer treatment
and attendance allowed them to express this gratitude.
‘I've been very lucky to survive because I had very advanced, you know,
cancer, so that's probably one of the reasons why I go, is to sort of, repay
the doctors for, you know, the care they did, the care they gave me’. (IR
12)
Not all CCS felt motivated to attend. Some discussed how the initial
letter, at the point of transition inviting the patient to the LTFU clinic
could have been considered a barriers for attending.
‘To be honest if you think you are provided with a letter, saying, you
know we are monitoring for late effects of a horrible cancer you had
previously, it's not the nicest thing.’ (IR 11)
Many (n = 9) of the CCS interviewed reported mixed emotions
following attendance at the clinic. Feelings experienced included; an-
xiety or slight apprehension prior to an appointment as a result of any
late effects experienced or relapse of disease.
‘I mean I do get a little bit panicky sometimes but, as I always worry that
they're going tell me, another, you know, late effect that they've found,
that I could be at risk of … because I've had the heart and I've had the
eggs, so I think what's the next one going to be … always get anxious
when I get my bloods done, just in case my blood count shows anything.’
(IR 12)
These feelings were often followed by a sense of relief and re-
assurance that they were no subsequent concerns following attendance
at their appointment.
‘If anything it's a nice reprieve, especially as occasionally you start over
thinking things. I haven't been for a while, what if this, what if, so it's nice
… to go in and have a check over and kind of clear your mind a bit.’ (IR
13)
Table 2
Type of childhood cancer treated.
Type of childhood cancer Questionnaire respondents n (%) Interview participants n (%)
Leukaemia (cancer of the blood e.g. Acute lymphoblastic leukaemia, Acute myeloid leukaemia) 22 (20%) 2 (15%)
Lymphoma (cancer of the immune system e.g. Hodgkin Lymphoma, Non-Hodgkin Lymphoma) 28 (25%) 4 (31%)
Solid tumour
The response categories selected were: 53 (49%) 7 (54%)
• brain/spinal/CNS tumour (n = 35, 32%)• kidney/renal tumour (n = 9, 8%)• soft tissue sarcoma (n = 7, 6%),• cancer of the bone’ (n = 1, 1%)• missing (n = 1, 1%)
Other:
• Aplastic Anaemia (n = 1) 7 (6%) 0• Thyroid cancer (n = 2)• Optic glioma, Melanoma (n = 2)• Wilms tumour (n = 1)• Ewing's sarcoma (n = 1)
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Despite the majority (n = 97, 86%) of CCS in the study feeling
motivated to engage with long-term follow-up services, many en-
countered barriers to attending clinic which included; the burden of
travelling long distances to attend clinic visits (n = 48, 48%) as well as
co-ordinating appointments around work commitments (n = 43, 36%).
Many of the CCS had experienced co-morbidities which created diffi-
culties and posed challenges in having to attend multiple appointments
at different sites with different specialists. More complex patients were
keen to see services streamlined where multi-disciplinary professionals
were working more collaboratively.
“it would be good, to have all the specialists in one place in one day so
that people can get it all over and done with, … and then he'd [con-
sultant] see more people as well, because if they've got loads of clinics to
go to, they [patients] won't want to bother.” (IR 8)
3.2. Knowledge of cancer treatment and potential late effects
In the survey some CCS acknowledged they did not feel well in-
formed regarding the rationale for attending the LTFU clinic (n = 24,
21%) nor about the late-effects risks they may face (n = 44, 41%) in the
survivorship period. Interview participants expanded on this saying
they did not remember being directly given any literature about why
they should attend the clinic or their potential late effects.
‘I've never really been given literature or anything as to why I attend, or
not that I'm aware of anyway. It's just, I understand I've got to go for
check-ups every x amount of years just to make sure I'm still doing ok so
that's the extent of my sort of understanding … I've never had any pa-
perwork or literature explaining what the reason is behind, you know,
what they're looking for.’ (IR 2)
Information relating to treatment and potential late effects were
often provided to parents at the time of diagnosis and treatment. There
were often not relayed to the child or were discussed several years ago
and therefore the information was not retained in many cases.
‘I do think they did tell me what I was at risk of but I can't remember
because it was quite a few years ago. You would be better asking my
mum on that one as she knows …. .she has all of her files still.’ (IR 13)
One CCS decided to ask the nurse about her original treatment and
was provided with information that she had not previously known:
‘I found out it was combination chemotherapy because I thought it was
like just one and I found out it was actually three. I found out that the
tablet they'd given me to help stop my periods, they'd actually given me
too high a dose and that's why I went through the change. I found out
quite a lot that I didn't actually know, that nobody had explained to me.’
(IR 10)
One CCS became distressed during the interview when she spoke of
a late effect that she had not previously been aware of and was a direct
consequence of her childhood cancer treatment.
‘I developed, well, what I know now to be (name of late effect) which was
probably from the chemotherapy but I didn't know that that's what it was
… But it's never, ever been explained to me. It's just turn up and see how
you are and then send you off again [at the clinic] … I finally went back
and my consultant said, oh yes, …you will have had that from the
radiotherapy. So that really upset me, because no one had ever said and
no one had told me to expect that.’ (IR 11)
In relation to knowledge about treatment and late effects both
questionnaire and interview participants were asked whether they had
a treatment/survivorship plan. Most questionnaire respondents in-
dicated that they had not received a treatment/care/survivorship plan
(n = 72, 66%) or were unsure if they had one (n = 29, 27%). Only
eight respondents (7%) reported having a follow-up care plan in place.
3.3. Suggested improvements to the current service
The interviewees who used the Late Effects clinic and telephone
service were also asked what they felt could be improved. One CCS felt
that they should be treated in clinic with more consideration of their
individual circumstances:
‘If there was one thing that I wished that they did differently, …I wish
they'd treat each person a little bit differently you know, as to how it's
affected them, not as a whole.’ (IR10)
Another CCS spoke of how the name ‘Late Effects Clinic’ could be
interpreted as ‘scary’:
‘I personally, I think they might need to change the name …. I think that
would just scare people to be honest.’ (IR 11)
One CCS spoke about the use of technology to provide reminders
given the long gap between appointments:
‘I mean, the only thing is that they give you the appointment for the next
two years on a card and you've got to keep this card safe for two years
…. So it would be nice if you got, you know a text.’ (IR 12)
Several of the CCS had multiple co-morbidities which can lead to
many face-to-face appointments at different sites for check-ups. These
more complex CCS were keen to see some streamlining in the way the
multiple professionals worked together:
‘I'd love it to be everything all in one day, check out my heart, kidneys,
have the specialists there or the, you know, able to go and get x-rays, or
scans, echo scans things like that all on one day, and do a sort of like
MOT of your body in one day.’ (IR 5)
One CCS felt that each patient should be able to choose whether
they attend the face-to-face clinic or a telephone clinic for each of their
appointments:
‘I think it might be easier if people when they get the appointment, they
should be able to say whether they want to go to the clinic or if they need
a phone consultation.’ (IR8)
Another CCS felt that it would be greatly beneficial to have some
continuity of service in regards to the staff they see during appoint-
ments:
‘I keep seeing different people when I attend clinic” (QR12)
It was highlighted by some of the CCS that they were not completely
clear of the reason that they were to attend the LEC and highlighted a
need for written information regarding the purpose of the late effects
appointments:
‘I've never really been given literature or anything as to why you know,
why I attend,…. It's just, I understand I've got to go for check-ups every x
amount of years just to make sure I'm still doing ok so that's the extent of
my sort of understanding … I've never had any paperwork or literature
explaining what the reason is behind, you know, what they're looking
for.’ (IR 2)
Some CSS discussed a need for the information about late effects to
be reiterated periodically:
‘I was 22 (age at interview 43) when I was told what might happen, and I
feel like I'd like to be told again, and if they know any more now, because
that was a long time ago and do they know what has happened to other
people and what might happen to me and, I don't feel, I feel, I'm not sure
how well informed I feel really’. (IR 5)
Another CCS felt a little confused as to exactly why they were at-
tending the clinic:
‘Unsure of what I should be getting out of these appointments and
unaware of how much or little they are aware of my case. Not aware of any
plan or information of what my long term effects could be?’ (QR 103).
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4. Discussion
The aim of the National Cancer Survivorship Initiative is to “ensure
that those living… beyond cancer get the care and support they need to lead
as healthy and active a life as possible” (http://www.ncsi.org.uk). Our
findings highlight further work that needs to be conducted in this area
to ensure that informational, interpersonal, and practical factors are
considered if CCS are to receive the information and appropriate ser-
vices to meet their specialised needs. For CCS to engage in LTFU care
their information needs and motivations need to be acknowledged and
addressed. Our findings indicate that a key influencer regarding the
decision to attend LTFU care is the information and knowledge a CCS
receives about their cancer treatment, risk of late effects and on-going
care. The CCS who receives limited information regarding late effects
consequences and has a poorer understanding of their treatment his-
tory, seemed less likely to engage in the LTFU clinics or services
available.
Despite recommendations for changes in practice to improve in-
formation offered to CCS including treatment summaries and survi-
vorship plans (Singer et al., 2013), our findings support existing lit-
erature which shows that many CCS continue to report poor levels of
knowledge Kirchhoff et al., 2014, Lindell et al., 2015, Quillen et al.,
2017). Most CCS in this study (93%, n = 101) either did not have any
form of care/survivorship plan or were unsure whether they ever had a
plan in place. This may be due to the majority of survivors having
completed treatment more than five years ago. Our findings also in-
dicate that parents are often the primary source of information re-
garding their child's cancer treatment. Difficulties can arise when this
information is not passed from parent to child or when cancer treatment
is complete and the child enters into adulthood without their prior
cancer history. The provision of written information at key intervals
such as at transition, including provision of treatment summaries or
survivorship care plans are all important components in ensuring that
CCS have adequate knowledge and understanding of their previous
diagnosis, treatment and the potential late effects of their cancer
treatment (Lindell et al., 2015; Quillen et al., 2017). Despite various
approaches to improve engagement within healthcare systems globally
and nationally, the current study, as reported elsewhere (Quillen et al.,
2017; Howard et al., 2018), suggests further improvements are required
to ensure provision of adequate information at key intervals of the CCS
journey. Simple steps such as reviewing and revisiting important cancer
information verbally and in writing when a child transitions into LTFU
care can increase CCS understanding of their diagnosis, treatment, and
late effects and potentially enhance their motivation to attend LTFU for
ongoing surveillance and management.
CCS should be asked about the level and type of information they
desire, how satisfied they are with the information received, and be
provided with regular opportunities to voice their needs and concerns.
Information tailored to the preferences of the CCS are important in
ensuring supportive care is appropriate and meaningful to the in-
dividual. The personal information recollection regarding their histor-
ical treatment or their recollection of what they been told about po-
tential late effects can vary dramatically between CCS. One way this can
be achieved is to inform CCS about the aims and benefits of long-term
follow-up and how decisions about care and treatment are jointly ne-
gotiated and agreed over time. The provision of treatment care-plans
can assist CCS to keep up-to-date with information about their condi-
tion, as well as providing the patients with relevant and timely in-
formation. Communication in the domain of long-term follow-up care
can be managed through Macmillan's recovery package interventions
targeted at self-management opportunities, quality of life issues, as well
as financial and work concerns (Macmillian Cancer Support, 2015a).
Although engagement in long-term follow up may increase anxiety
to some CCS by discussions centred on the patient's previous diagnosis
and treatment, many CCS expressed benefits from attending long-term
follow up care. Survivors in our study felt motivated to attend LTFU
clinics as they provided reassurance, following monitoring, that things
were ‘okay’, in addition to having access to information and specialist
staff. Some patients expressed feeling indebted to the health service and
their treating multidisciplinary team and therefore attended LTFU
clinics to express their appreciation.
However, CCS, could be dissuaded from attending LTFU clinic ap-
pointments if they had to navigate competing speciality appointments
alongside employment and family commitments. The challenge of at-
tending multiple appointments for CCS has been documented in the
literature (Howard et al., 2018; Granek et al., 2012) and seem to persist
despite calls to improve the co-ordination of survivorship care with
tailored follow up pathways and holistic packages of support which
address issues of complexity of needs and self-management
(Independent Cancer Taskforce, 2015a, 2015b). Some of these barriers
can be overcome by addressing organisational considerations, whether
simple measures like tele-health clinics or the use of mobile applica-
tions for those who are unable to physically attend clinics (Baseman
et al., 2017) or more significant re-structuring to offer age-appropriate,
multidisciplinary, one stop clinics (Gan, 2014) with multi-disciplinary
professionals at one clinic, which may be of particular value for those
considered to be at highest risk of serious or multiple late effects. The
decision for CCS to attend LTFU appointments is not simple and is in-
fluenced by a process of weighing up multiple motivations and prio-
rities against each of the challenges presented.
The CCS who participated in this study represents a small select
group of patients who are registered with the LTFU service. However,
despite all efforts by the study team, only one non-attender expressed
their views in the open-ended section of questions in the paper-based
questionnaire. Further efforts to engage with non-attenders is needed to
explore their reasons as well as to further identify methods for im-
proving follow-up care in this patient cohort.
In conclusion, this study reports on some benefits and barriers ex-
perienced by CCS in relation to LTFU care. Barriers presented included
CCSs' lack of knowledge in relation to their cancer treatment history,
the potential benefits associated with LTFU care, as well as the impact
of organisational and practical barriers which may include multiple and
competing appointments, as well as the location and timing of ap-
pointments. These barriers may be addressed through cancer service
strategies based on improving information discussed and disseminated,
use of care-plans, offering care closer to people's homes, nurse-led
clinics and telephone follow-up. Other strategies may involve; remote
surveillance such as tele-health and patient portals, and through risk
stratified pathways to encourage supported self-management based on
cancer type, co-morbidity, and level of professional involvement re-
quired (NHS, 2016). Earlier and more frequent supportive care inter-
ventions (NHS England, 2016) may mitigate the impact of late effects in
CCS based on enhanced co-ordination and integration of services, em-
pathetic communication, shared decision-making, and a focus on psy-
chological and physical wellbeing throughout the disease trajectory.
The use of holistic needs assessments in clinical practice (Macmillian
Cancer Support, 2015b) may also assist with identifying unmet psy-
chological needs and emotional concerns in CCS associated with fear,
anxiety and depression.
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